Jeffrey Boatright Research Group
The Problems YOU Tackle -- what is the overarching problem or set of problems your group talckes
The Focus of your group : what challenges within that problem/problems do you tackle
The Approach - how do you tackle it
The Boatright laboratory conducts research initiatives on gene therapy and neuroprotection in treatment of retinal degenerative diseases in the expectation that pharmacological neuroprotectants will delay vision loss while gene therapies will provide permanent relief.
Collaborating with researchers at Atlanta VA Medical Center, and using a study of an animal model of age-related macular degeneration, the Boatright Lab was one of the first to suggest that aerobic exercise can have a direct effect on retinal health and vision.
Current and Recent Research of the Jeffrey Boatright Group
Lorem ipsum dolor sit amet
TITLE of RESEARCH
Sponsors:
Collaborators:
Publications & Presentations: Autophagy (2022); ARVO Annual Meeting (2022)
Sayantan Datta and the Macular Degeneration Group discovered a novel mitochondrial retrograde signaling where mitophagic impairment through Pink1 silencing alone was able to drive EMT of the RPE cells and interestingly this pathway was critically dependent on the oxidative stress response pathway. Please check our latest publication on this published in the journal Autophagy:
TITLE of RESEARCH
Sponsors:
Collaborators:
Publications & Presentations:
Our RNA seq studies revealed that STAT1 mediated interferon signaling is a key player in controlling EMT and cell viability in the RPE and we are investigating how interferon signaling connects to mitochondrial dysfunction and cell fate in the RPE.